Providing research teams with immediate access to high-quality, HLA-typed, well-characterized immune cells to accelerate oncology and immunology research.
Founded in 2026, Alluxion Biosciences was created with a bold vision: to streamline discovery in the life sciences by delivering high-quality, ready-to-use cell materials to research teams when and where they need them.
Our mission is to improve the number of successful drug developments by strengthening early-stage research. We aim to remove barriers that drive high costs and long delays—such as limited access to cell materials optimized for donor-to-donor research through HLA typing for research use, reliance on animal models, and nonclinical study support developed with regulatory considerations in mind. These challenges often place a significant burden on research programs.
Our team of specialists in stem cells, cell biology, immunology, nonclinical studies, and biotechnology operations brings deep technical experience and a strong commitment to helping our partners in biotech reach meaningful milestones. We collaborate with labs, startups, and institutions worldwide to empower innovation through practical, scalable support that advances programs toward IND submission.
Whether you're running a single experiment or scaling a pipeline, Alluxion Biosciences supports your work with reliable cell materials, rapid access, and practical expertise.